Goodwin Procter advised Nimbus Therapeutics in connection with its recently completed $43 million Series B financing led by Pfizer Venture Investments and Lightstone Ventures. The company’s newest round of funding was oversubscribed and included all of company’s Series A investors. Concurrent with the announced funding, Nimbus also changed its name from “Nimbus Discovery” to “Nimbus Therapeutics.”
Nimbus Therapeutics, based in Cambridge, Mass., harnesses the power of computational chemistry to design breakthroughs for the treatment of substantial and underserved human diseases. The company’s focus on metabolic diseases, cancer and immune-inflammatory disorders is driven by its selection of well validated targets that have proven intractable to the approaches taken by others in the pharmaceutical and biotechnology industry. Using its unique approach and technological capabilities, Nimbus is rapidly progressing highly selective and potent small molecules through discovery and development. The company’s advanced programs include ACC, IRAK4, and Tyk2.
The Goodwin team advising Nimbus included Mitch Bloom, Bill Collins, Art McGivern (corporate), Bill Whitledge and Dan Karelitz (tax).